Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
Chan
C
C
Bartolucci
A
A
Brenner
D
D
Presant
C
C
Davila
E
E
Carpenter
J
J
Greco
F A
FA
Clamon
G
G
Moore
J
J
D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D001389:Azirines / Q000627:therapeutic use*; D016227:Benzoquinones; D001859:Bone Neoplasms / Q000188:drug therapy*; D004341:Drug Evaluation; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009279:Naphthacenes / Q000627:therapeutic use; D012509:Sarcoma / Q000188:drug therapy*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy*
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D001388:Aziridines; D001389:Azirines; D016227:Benzoquinones; D009279:Naphthacenes; C029108:diaziquone